Ask the Experts: Renal and Urology News

Why Racial and Ethnic Disparities Exist in Kidney Disease Care

Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.

Multiple patients having chemotherapy in a room

Algorithm Proposed to Expand Cisplatin Eligibility for MIBC

A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.

Nearly 40% of This Nephrologist’s ESKD Patients Dialyze at Home

Shaminder Gupta, MD, tells Renal & Urology News how he developed and manages a home dialysis program in which approximately 40% of his patients with end-stage kidney disease (ESKD) participate, far above the national average in the United States.

Highlights From the National Kidney Foundation 2020 Spring Clinical Meetings

Joseph A. Vassalotti, MD, the National Kidney Foundation’s Chief Medical Officer, moderated a late-breaker abstract session at NKF’s Spring Clinical Meetings. Renal & Urology News asked him for his takeaways.

Sipuleucel-T Survival Benefit Greater in Black Men

Andrew J. Armstrong, MD, and colleagues looked at men with metastatic castration-resistant prostate cancer treated with sipuleucel-T in the PROCEED registry. Study findings demonstrated that African-American men experienced a substantially greater survival benefit from the immunotherapy than Caucasian men.

Subclassification of High-Risk Prostate Cancer Validated

Vinayak Muralidhar, MD, and colleagues compared a subgroup of men with favorable high-risk PCa (T1c with either a Gleason score of 4+4 = 8 and a PSA level below 10 ng/mL or a Gleason score of 6 and a PSA level greater than 20 ng/mL) with standard high-risk disease.

Comparative Harms of Prostate Cancer Management Approaches

Karen E. Hoffman, MD, MHSc, MPH, and colleagues examined the comparative harms of contemporary treatments for localized prostate cancer through 5 years in favorable and unfavorable risk patients.

Facility-Level Variation in Use of Pelvic Lymphadenectomy in High-Risk Prostate Cancer

David F. Friedlander, MD, MPH, and his colleagues examined facility-level variation in the performance of pelvic lymphadenectomy during radical prostatectomy for high-risk prostate cancer and its effect on overall survival.

Meeting Highlights From LUGPA 2019

Renal & Urology News discussed the annual LUGPA meeting with Mara R. Holton, MD, who sits on LUGPA’s board of directors and is the organization’s vice chair of health policy.

Novel Agent May Improve Renal Anemia Management

Dr Provenzano has conducted extensive research on the management of anemia in patients with kidney disease.

Surgical Castration for de novo Metastatic Prostate Cancer

Dr Adam B. Weiner led a study evaluating temporal trends and factors associated with the use of surgical castration for men with de novo metastatic prostate cancer.

Potassium Binders Offer Improved Hyperkalemia Management, CKD Care

Dr Agarwal led the phase 2 AMBER study, which looked at the effectiveness of the oral potassium binder patiromer on the persistence of spironolactone use in patients with advanced chronic kidney disease (CKD) and resistant hypertension.

Management Issues in Metastatic Prostate Cancer

Amar U. Kishan, MD, and Jad Chahoud, MD, MPH, discuss their strategies for managing metastatic castration-sensitive prostate cancer.

Germline Testing for Prostate Cancer Active Surveillance

Brian T. Helfand, MD, PhD, discussed germline testing for prostate cancer prognosis and its implications for active surveillance at the Philadelphia Prostate Cancer Consensus Conference: Implementation of Genetic Testing for Inherited Prostate Cancer.

Focal Laser Ablation of Prostate Tumors With Gold Nanoparticles

How does this procedure compare with other ablative therapies for prostate cancer? Where does the research go from here? Find out what this expert had to say about a new method for treating prostate cancer.

Review Now

Using Novel Anti-Androgens in Non-Metastatic CRPC

What should be the basis for starting non-metastatic CRPC patients on one of the novel anti-androgens?

Pharmacologic Therapy for CRPC

At the 2019 annual meeting of the American Urological Association (AUA), Dr Jarrard was a member of the instructional faculty in a session titled “AUA Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer.”

Expert Perspectives